Abstract
Clinical presentations of COVID-19 exhibit a relative variation that might have roots in various circumstances. The initial infectious dose is a decisive factor in determining the fate of some viral and bacterial infections. Regarding the importance of inflammation and immunopathogenesis in the progression of COVID-19, the initial infectious dose of severe acute respiratory syndrome coronavirus 2 might have an impact on the initial inflammation and therefore the incubation period of the disease. A quick progression to severe disease might decrease the chance for successful therapy. Therefore, more release of danger-associated molecular patterns and more cytokine responses are expectable in the case of higher infectious doses. Herein we discuss the impact of initial infectious dose in the pathogenesis of similar infections such as MERS and influenza.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.